PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
about
Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breastThe molecular background of mucinous carcinoma beyond MUC2Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumorsPIK3CA mutations in in situ and invasive breast carcinomas.Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis.The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models.Elevated PI3K signaling drives multiple breast cancer subtypes.Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Biologic characteristics of premalignant breast disease.What is the malignant nature of human ductal carcinoma in situ?Attacking breast cancer at the preinvasion stage by targeting autophagy.PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors.Ductal carcinoma in situ - update on risk assessment and management.PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis.Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
P2860
Q28083103-432D4A84-E4D2-4871-8E64-4837A3009789Q28083904-70B1C0DF-CAC0-48B4-8F66-68EA03F8BD5BQ28729079-AA3DBF82-E376-4F29-BEC7-9AF90F5FF464Q34001222-5B98A831-E555-4B84-93D0-803D8765B460Q34112879-BCDA2A76-B9C9-4B95-B0BB-C6456CF91B6AQ34229795-C8D18B75-B51C-48C5-B158-2C478C6F9518Q35640263-7E9AFC00-5013-4255-B480-32160DE172B3Q35861503-F65F02FA-CB31-45E8-82CB-E9B6EC0F36B3Q36204798-76FAAB10-C1A1-4A9F-B95E-0416D6B3A4E6Q37130512-FA3758F4-4894-400E-AF5C-3DD1F51BCA86Q37188353-1EBB81FD-7F07-455B-A6D4-B0E69B868E5BQ37589094-E1503FE7-1533-4CB0-B8FE-4A26A2CAE54EQ38079299-98E8C3CE-7F0A-425C-B8E6-8058890B43B5Q38696796-460A68ED-F0AF-4176-8B80-2D24D72D6233Q46614726-A5E0D80F-5894-4793-9B93-3B1DDE60C2CEQ46699535-42C10CDF-216A-46FD-A276-422F4BBDED25Q48365186-F2AA6324-3926-49ED-8408-5ECE5DDE2562Q49179749-EFE14654-D9BF-42DB-9B15-1245DDE6BF24Q53272132-F1E3A602-5133-472B-9533-B5BC75A96A26Q54399355-A0DA64C8-2F4D-448F-BFF4-A53199F4653E
P2860
PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
@ast
PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
@en
type
label
PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
@ast
PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
@en
prefLabel
PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
@ast
PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
@en
P2093
P1476
PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
@en
P2093
Hongguang Zhu
Tengfang Zhu
P304
P356
10.1016/J.YEXMP.2009.09.016
P577
2009-10-08T00:00:00Z